Uplizna (inebilizumab-cdon) safely prevented autoimmune attacks in 83% of people with neuromyelitis optica spectrum disorder (NMOSD) who received the treatment for four or more years, data from the N-MOmentum Phase 2/3 clinical trial show. Among those who experienced relapses, most did so during the first year of treatment.
Almost half of U.S. patients with neuromyelitis optica spectrum disorder (NMOSD) experienced relapses over a period of two years, according to an analysis of a large healthcare claims database. Such relapses — which lasted on average nearly 13 days — were treated more often with outpatient rather than hospital…
Enspryng (satralizumab), a therapy for adolescents and adults with neuromyelitis optica spectrum disorder (NMOSD), has been recommended for reimbursement through Canada’s public drug plans, if certain conditions are met. Among the conditions established by the Canadian Drug…
The autoimmune biomarker CH50 was directly impacted by treatment with Soliris (eculizumab) in three people with neuromyelitis optica spectrum disorder (NMOSD), a case report has shown. According to researchers, this suggests that CH50 may be a useful…
Enspryng has been approved by the Taiwan Food and Drug Administration for treating people 12 and older who have aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), Chugai Pharmaceutical announced. The import drug license…
Get regular updates to your inbox.